751 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Monday’s Close
BMY Bristol-Myers Squibb Company $61.3 $100.03B Sell
Article Searches
Top Gene-Sequencing Stocks for 2019 https://www.fool.com/investing/2019/04/19/top-gene-sequencing-stocks-for-2019.aspx?source=iedfolrf0000001 Apr 19, 2019 - These next-generation companies are working on game-changing ways to obtain and profit from genetic insight.
Bristol-Myers Squibb (BMY) Reports Next Week: Wall Street Expects Earnings Growth http://www.zacks.com/stock/news/386894/bristol-myers-squibb-bmy-reports-next-week-wall-street-expects-earnings-growth?cid=CS-ZC-FT-386894 Apr 18, 2019 - Bristol-Myers (BMY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Biotech Stock Roundup: GILD Collaborates on NASH, FCSC Surges on Deal http://www.zacks.com/stock/news/382518/biotech-stock-roundup-gild-collaborates-on-nash-fcsc-surges-on-deal?cid=CS-ZC-FT-382518 Apr 17, 2019 - Key highlights of the past week are collaborations and pipeline updates.
Why Celgene Shareholders Should Hold On to Their Bristol-Myers Squibb Stock Once the Acquisition Closes https://www.fool.com/investing/2019/04/16/why-celgene-shareholders-should-hold-on-to-their-b.aspx?source=iedfolrf0000001 Apr 16, 2019 - The fat lady is getting ready to sing with this big pharma deal. Celgene shareholders will soon have a decision to make.
Bristol-Myers' Shareholders Vote for Celgene Acquisition http://www.zacks.com/stock/news/381001/bristol-myers-shareholders-vote-for-celgene-acquisition?cid=CS-ZC-FT-381001 Apr 15, 2019 - Bristol-Myers' (BMY) gets a green signal from a majority of its shareholders for the merger with Celgene Corporation.
Clovis Stalls Mid-Stage Rubraca Study for Bladder Cancer http://www.zacks.com/stock/news/380655/clovis-stalls-mid-stage-rubraca-study-for-bladder-cancer?cid=CS-ZC-FT-380655 Apr 15, 2019 - Clovis Oncology (CLVS) halts mid-stage bladder cancer study evaluating Rubraca monotherapy. It is unlikely to provide meaningful clinical benefit as reviewed by an independent data monitoring committee.
Pharma Stock Roundup: AZN, MRK, GSK Get Regulatory Approvals, Sandoz Inks New Deal http://www.zacks.com/stock/news/379777/pharma-stock-roundup-azn-mrk-gsk-get-regulatory-approvals-sandoz-inks-new-deal?cid=CS-ZC-FT-379777 Apr 12, 2019 - Glaxo (GSK) gets FDA approval for a new HIV medicine, Dovato. AstraZeneca (AZN)/Merck's (MRK) Lynparza gets approval in EU for metastatic breast cancer.
Seattle Genetics' Adcetris Progresses Well Amid Competition http://www.zacks.com/stock/news/379195/seattle-genetics-adcetris-progresses-well-amid-competition?cid=CS-ZC-FT-379195 Apr 11, 2019 - Seattle Genetics (SEGN) focuses on improving sales of its flagship product, Adcetris. The drug's label expansion programs also appear encouraging.
Celgene & Acceleron Submit BLA for Luspatercept to the FDA http://www.zacks.com/stock/news/372710/celgene-acceleron-submit-bla-for-luspatercept-to-the-fda?cid=CS-ZC-FT-372710 Apr 08, 2019 - Celgene (CELG) and partner Acceleron submit BLA for pipeline candidate, luspatercept to the FDA.
Why the Earnings Surprise Streak Could Continue for Bristol-Myers (BMY) http://www.zacks.com/stock/news/372339/why-the-earnings-surprise-streak-could-continue-for-bristol-myers-bmy?cid=CS-ZC-FT-372339 Apr 08, 2019 - Bristol-Myers (BMY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Pages: 123456...76

Page 1>